Kenneth Thress (AstraZeneca) Using NGS w/3rd-gen TKIs; C797S-mediated acquired resistance. '15 ref https://t.co/tLtZCRxcLJ #FDA-AACR

11:07am July 19th 2016 via Hootsuite